Neurogene (NASDAQ:NGNE) Price Target Raised to $72.00 at Leerink Partners

Neurogene (NASDAQ:NGNE) had its target price upped by investment analysts at Leerink Partners from $45.00 to $72.00 in a research note issued on Tuesday,Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Leerink Partners’ price objective points to a potential upside of 81.54% from the company’s previous close.

Other research analysts also recently issued research reports about the stock. HC Wainwright upped their price target on shares of Neurogene from $49.00 to $55.00 and gave the stock a “buy” rating in a research report on Tuesday. Robert W. Baird upped their target price on shares of Neurogene from $54.00 to $72.00 and gave the stock an “outperform” rating in a research report on Tuesday. Eight analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $63.33.

Neurogene Stock Down 0.9 %

NGNE stock opened at $39.66 on Tuesday. The business has a fifty day moving average price of $46.91 and a 200 day moving average price of $40.12. Neurogene has a fifty-two week low of $12.49 and a fifty-two week high of $74.49.

Institutional Investors Weigh In On Neurogene

Institutional investors and hedge funds have recently modified their holdings of the business. Charles Schwab Investment Management Inc. grew its holdings in Neurogene by 2.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 30,317 shares of the company’s stock worth $1,272,000 after acquiring an additional 741 shares during the period. BNP Paribas Financial Markets grew its position in shares of Neurogene by 192.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,170 shares of the company’s stock worth $91,000 after buying an additional 1,429 shares during the period. Quest Partners LLC acquired a new position in shares of Neurogene during the 2nd quarter worth about $55,000. SG Americas Securities LLC bought a new stake in shares of Neurogene in the 1st quarter valued at about $120,000. Finally, Baker BROS. Advisors LP raised its position in shares of Neurogene by 0.6% in the 1st quarter. Baker BROS. Advisors LP now owns 456,015 shares of the company’s stock valued at $23,211,000 after acquiring an additional 2,499 shares during the period. 52.37% of the stock is owned by institutional investors.

About Neurogene

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.